Abstract:It has been reported that up to 87% of individuals with MetS have dyslipidemia (3). Given this, research into the key factors regulating lipid homeostasis in MetS and its comorbidities has received a vast amount of attention. In this Research Topic, Nauli et al. explored the effects of sex hormones on the size of intestinal lipoproteins that carry dietary lipids to the periphery (4). Compared to women, men are more prone to central obesity, one of the five conditions that comprise MetS. Using the conscious lymph fistula mouse model, the authors discovered that male mice produced larger intestinal lipoproteins than female mice when intraduodenally infused with lipid emulsion (4). Larger lipoproteins may contribute to central obesity by facilitating increased fat uptake in visceral abdominal adipose tissue. Further investigations leveraging the Caco-2 cell model showed that testosterone significantly increased the size of lipoproteins in a dose-dependent manner (4). Regarding whole-body cholesterol balance, Banerjee et al. reported that, unlike the Aster-B protein, which plays an essential role in cholesterol transport and downstream esterification, the non-vasicular Aster-C protein (encoded by Gramd1c gene) played a minor role in whole-body cholesterol balance in a sophisticated study including divergent dietary cholesterol and Gramd1c knockout mouse model (5). The gut hormone glucagon-like peptide-2 (GLP-2) has been shown to play pleiotropic roles in regulating lipid handling in the intestine, which is important for maintaining energy homeostasis and cardiometabolic health. In the review by Mukherjee and Xiao, the authors elucidated the mechanisms of GLP-2 in regulating post-prandial lipid absorption and post-absorptive release of intestinally stored lipids (6). While further summarizing the role of GLP-2 in metabolic disorders, the authors discussed the opportunities to promote health benefits beyond its current clinical use for treating shortbowel syndrome by manipulating GLP-2 mediated pathways (6).MetS is closely linked to dysregulated energy homeostasis. Engaging in daily physical activities has become the first choice in clinics for managing MetS. Physical activities are well known for body weight management by promoting energy expenditure. However, the impact of physical activities on CVD-related HDL function has yet to be further studied. In a human study including healthy lean, obese, and type 2 diabetic subjects, Zhu et al. demonstrated that a short-term highintensity interval training (HIIT) program improved HDL function depending on metabolic contexts, correlating with improvements in blood lipid profile (7). This study showed that triacylglycerol content in HDL particles may negatively affect the anti-atherogenic function of HDL (7). Furthermore, Sadler et al. quantified the impact of protonophore treatment on wholebody energetics in mice housed at 30 o C, a thermoneutral housing that may mask the effects of anti-obesity strategies on energy expenditure (8). They observed that mice housed at 30 o C showed reduced basal energy expenditure compared to 24 o C controls, and protonophore treatment markedly increased energy expenditure, resulting in reduced adiposity in mice housed at 30 o C (8). Nicotinamide N-methyltransferase (NNMT) is involved in energy expenditure by lowering NAD + content via catalyzing the methylation of nicotinamide. Sun et al. reviewed the current understanding of the role of NNMT in MetS (9). Single nucleotide variants in the NNMT gene are significantly correlated with disturbances in energy metabolism; elevated NNMT gene expression is notably observed in the liver and white adipose tissues of obese individuals (9). In animal models, knockdown NNMT expression with RNAi strategies or small molecule inhibitors improved MetS-related diseases (9).Lipodystrophy syndromes are rare diseases, and delays in diagnosis may predispose to the development of severe metabolic complications and end-organ damage. A rapid action plan was developed by Fourman et al. using insights gathered through a series of advisory meetings with clinical experts from multiple countries (10). The Rapid Action Plan includes clinical and family history, physical exams and laboratory criteria, diagnostic tools of imaging and genetic testing, as well as guidelines for the syndrome treatment and management (10). Along with a commentary article by Massey and Zhu, discussions in the Rapid Action Plan highlighted the significant role of adipose tissues in MetS (10; 11). Another clinically relevant research article in this Research Topic is by Bukara-Radujkovic et al., who demonstrated the role of glycemia risk index in managing blood glucose in routine clinical practice by exploring the correlation of traditional parameters, such as HbA1c, and novel parameters, including glycemia risk index and time-inrange, in pediatric patients with type 1 diabetes (12).Additional -Abstract Truncated-

The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature

Recent Developments in Delivery of MicroRNAs Utilizing Nanosystems for Metabolic Syndrome Therapy

Comprehensive Review on Lipid Metabolism and RNA Methylation: Biological Mechanisms, Perspectives and Challenges

A Mechanistic Review on Therapeutic Potential of Medicinal Plants and their Pharmacologically Active Molecules for Targeting Metabolic Syndrome

A New Insight into the Roles of MiRNAs in Metabolic Syndrome

RNA therapeutics for metabolic disorders

Recent advances in molecular biology of metabolic syndrome pathophysiology: endothelial dysfunction as a potential therapeutic target

Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome

Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies

Research advances in the therapy of metabolic syndrome

Key Correlated Pathologies and Non-Invasive Diagnostic Approaches

Editorial: Strategies to overcome metabolic syndrome and related diseases

Nuclear Receptor ROR/: Exciting Modulators in Metabolic Syndrome and Related Disorders

The role of microRNAs in the regulation of insulin signaling pathway with respect to metabolic and mitogenic cascades: A review

Current Advances in RNA Therapeutics for Human Diseases

RNA in cardiovascular disease: A new frontier of personalized medicine

Stem cells as a potential therapy in managing various disorders of metabolic syndrome: a systematic review

Pharmacological treatment and therapeutic perspectives of metabolic syndrome

siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive review of molecular targets

Novel insights into transfer RNA-derived small RNA (tsRNA) in cardio-metabolic diseases

Current RNA strategies in treating cardiovascular diseases